Benzinga

Benzinga

Benzinga

lundi, août 24

ACADIA Pharmaceuticals Inc

ACADNASDAQ
Trade with Public
Trade with Public
$29.50
0.461.58%
À la clôture: Aug 20, 5:00 PM EST
$30.02
0.983.37%
Pré-ouverture: 3:00 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

ACADIA Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ACADIA Pharmaceuticals (ACAD).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

2S.Buy
15Buy
3Hold
1Sell
Consensus RatingBuy# Analysts21Avg. Consensus PT$32Upside to Avg. PT+5.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026UBSAshwani VermaPT RaiseBuy$45→$49
Aug 12, 2026NeedhamAmi FadiaPT RaiseBuy$38→$41
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.
Benzinga Newsdesk

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25

Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $37.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises the price target from $35 to $36.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved